Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with wild‐type (wild‐type mCRC. including an irinotecan‐based regimen but not an EGFR inhibitor. Adjuvant chemotherapy was allowed to be counted as a line of therapy if disease progression/recurrence had occurred ≤6 months after completing treatment. Patients were required to be ≥18 years… Continue reading Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment